Overcoming aspirin resistance: Increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease [2]

Thrombosis and Haemostasis

Volumn 95, Issue 6, 2006, Pages 1042-1043

  Wong, Shen ^a   Morel Kopp, Marie Christine ^a,b   Chen, Qiang ^a,b   Appleberg, Michael ^a   Ward, Christopher M ^a,b   Lewis, David R ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; CLOPIDOGREL; VON WILLEBRAND FACTOR;

ADULT; AGED; BIOASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; HUMAN; LETTER; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE FUNCTION; TURBIDIMETRY; VALIDATION PROCESS; WILCOXON SIGNED RANKS TEST;

AGED; AGED, 80 AND OVER; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 33745325634     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-12-0808     Document Type: Letter

References (11)

1. Cassar K, Bachoo P, Brittenden J. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg 2003; 25: 6-15.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
4. Wong S, Appleberg M, Ward C, et al. Aspirin resistance in cardiovascular disease: A review. Eur J Vasc Endovasc Surg 2004; 27: 456-65.
5. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
6. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. [see comment]. Am J Cardiol 2001; 88: 230-5.
7. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62: 165-74.
8. Hung J, Lam JY, Lacoste L, et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
9. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80-5.
10. Yusuf S, Zhao F, Mehta SR, et al., The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
11. Perneby C, Wallen NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-8.